Divella et al. found that SERPINE1 polymorphism can be used as a prognostic indicator for HCC patients receiving TACE, but its underlying molecular mechanism has not been explored (Divella et al., 2015). This evidence concerns the gene SERPINE1 and hepatocellular carcinoma.